BBMRI NL Hub 10 HoBB special. Hub
|
|
- Nancy Gaines
- 8 years ago
- Views:
Transcription
1 Hub Hub is the official newsletter of BBMRI-NL BBMRI NL Hub 10 HoBB special HandsOn: Biobanks 2013 Special In this edition: 2 Highlights of HandsOn 6 Uta Francke 8 Stephen Birch 10 Henk-Jan Guchelaar 12 Column Jan-Eric Litton Connecting Communities
2 2 Hub 10 HoBB special Hub 10 HoBB special 3 HandsOn: Biobanks 2013 Highlights With some 320 visitors, HandsOn: Biobanks 2013 offered something for everyone. Everyone in any way concerned with or connected with biobanking, that is. From inspiring keynotes to educational sessions, from a poster competition to Idea Labs, from the DNA Lab CSI: The Hague to the Ethics Café sessions, and through everything the main thread: The Route. Our photographer Thijs Rooimanscreated a photographic impression of the conference, which you can view on our website Below are some of the highlights of the two days. Poster competition winner: Anna Sundby With her poster Whole genome sequencing new possibilities, new dilemmas, Anna Sundby from Aarhus University and The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Denmark, won first prize in the poster competition. The poster explores the ethical implications of whole genome sequencing and the views of research participants on the disclosure of findings, as well as consent procedures. On the photo, head of the poster competition committee Professor Gerhard Zielhuis hands Anna her prize, the ipad. Runners up were Noor Giesbertz, RUNMC (2nd prize), and Sandra Slagter, UMCG (3rd prize). The Route: interactive display of the biobanking process Jeannette Ridder-Numan from the Ministry of Education and Science was the first to walk The Route, the interactive exhibition of all the steps involved in biobanking: from Ethics and Regulation to Biobanking Practice and Pre-analytics, to Sample Analysis, Data Analysis and finally Dissemination. After signing an informed consent form and being handed her personal blood test tube, Ms. Winter proceeded to a LIMS, a DNA extractor, analysis equipment, and several examples of virtual catalogues and repositories. Ethics Café: ELSI issues up for debate and song On both Thursday and Friday, a large group os visitors gathered at the Ethics Café to discuss legal and ethical matters. On Thursday, the HeLa: How to Treat Her Right session attracted special notice when live music began to play. Joancy and Orville Breedveld treated the guests to classics from Sam Cooke and Jimi Hendrix, a.o. On Friday, the Ethics Café saw two opposing sides of the same question as Dr. Annelien Bredenoord and Professor Ellen Clayton discussed how to go about disclosing accidental findings to biobank participants. At the end of the session, a quick show of hands revealed that the audience was still divided between disclosure yes, if... and no, unless....
3 4 Hub 10 HoBB special Party! On Thursday night, many visitors let down their hair and kicked up their feet at the party in Madurodam theme park. Pop band La Stampa performed classics and contemporary hits, there was a fine food buffet and a chance to talk to whomever you had been too busy to talk to during the day. Idea Labs: This could be the beginning of a beautiful collaboration The Idea Labs, scheduled three times in the two-day programme, did exactly what they set out to do: they got people talking, and sowed the seeds for further collaborations. The concept of the Idea Labs is simple: put four experts and a moderator in a room with an interested audience, break away in four subgroups and let the audience decide what they want to discuss and with whom. Hub 10 HoBB special 5 Idea Lab 1, Best pracitices in multi-omics biomarker discovery, sparked a plan to set up a task force Sample Analysis, working towards standard operating procedures for sample collection, storage and quality control, under the leadership of Marcel Bruinenberg (LifeLines). Idea Lab 2, Standardizing the Changing World, Share Information in the Cloud Using Standard Protocols, veered towards an exploration of the legal possibilities and pitfalls of sharing data online. The participants in Idea Lab 3, Patient Input in Biobank and Patient Registries, concluded that closer connections between biobanks and patients or patient organizations is vital to forward research, and also pointed out the dangers in governmental over-regulating. Members of the Idea Lab team are already planning to set up a session at the 2014 HandsOn: Biobanks meeting in Helsinki. Professor Anu Jalanko (BBMRI.fi): HandsOn: 2014 in Helsinki, mark the date! On 24 and 25 September 2014, the third edition of HandsOn: Biobanks will take place in Helsinki, Finland, hosted by BBMRI.fi and Professor Anu Jalanko of the National Institute for Health and Welfare (THL) and Institute for Molecular Medicine Finland (FIMM). It is something of a responsibility!, declares Professor Jalanko. BBMRI.fi was involved in organizing the 2012 edition of HandsOn, but only as one of three parties. Having visited both editions, and viewing the efficiency and success of the conferences and their organizing teams, it seems quite a daunting task to take on. But I am very pleased that BBMRI Finland will get to host the third instalment of, hopefully, a long series of HandsOn: Biobanks conferences. Professor Jalanko is not planning to change the formula of the conference: No, why should I? The format is playful, highly interactive, and has proven to be highly successful. Not only on the days themselves, but afterwards, where collaborations have sprung up as a result of discussions during the Idea Lab sessions or The Route. Does she already have a subtheme in mind, or speakers she would like to invite? It s much too premature for that! Or rather, I m thinking, but not ready to disclose anything at so early a date. The only people I definitely do not hesitate to invite are the visitors we had in 2012 and 2013; and of course anybody concerned with biobanking who couldn t make it to the first two editions. We look forward to welcoming you to Helsinki in September 2014!
4 6 Hub 10 HoBB special Hub 10 HoBB special 7 Keynote 1: Uta Francke by Pieter van Megchelen Direct to consumer DNA testing, bottom-up initiatives by patient groups and the general public, private-public partnerships: the face of biomedical research is changing rapidly. Professor Uta Francke, professor emeritus at Stanford University and senior medical director of 23andMe addressed these themes in her keynote speech SNP s and surveys: Participant-driven research with self-reported data on Thursday 21 November. The research model is changing from an academic top-down model to a more bottom-up approach. It used to be mostly academic institutions who recruited subjects. Now the public has become a driving force, providing scientists with materials and data. I think it is amazing that so many people decide to participate in the scientific research by 23andMe. Altruism seems to be a motivating force. They want other people to benefit from the research based on information and materials they provide, says Francke. 23andMe offers direct-to-consumer DNA testing. Each participant also receives an invitation to be part of the company biobank and contribute phenotype information by responding to surveys. This fast-growing data bank is being used for genetic research on a wide variety of subjects by carrying out genome-wide association studies. Serious medical questions are being addressed, but also the heritability of the funny smell of urine after eating asparagus, or genetic factors in motion sickness. The facts and factoids from this research are not only published in the scientific literature, but also communicated on the 23andMe website. This helps to build a community. Of course our participants always have the right to revoke their permission. In that case their sample will be destroyed and their contributed data de-identified. In everything we do, we adhere to the highest standards of privacy protection and medical ethics. Privacy Many customers, especially people with diseases, decide to share their test results and other personal data, seeking advice from their peers and contributing to various online forums, some of them hosted by 23andMe. Whenever biomedical questions are raised, staff scientists try to provide state-of-the-art answers. Francke: Especially the younger generation is not so much concerned with privacy and likes to share things online. The very business model of 23andMe has attracted criticism. Theoretically, there could be a danger in telling people about their disease risks. What if they decide to change their lifestyle or become seriously depressed because of the information or even a misunderstanding? And then, there are of course the same concerns about privacy and diligence as in any medical diagnostic setting. Francke is aware of these potential sources of problems, but emphasizes the advantages of direct access to DNA analysis: DNA gives people information about their origins. This is especially interesting in the United States, where many people have a mixed ethnic background. They like to know if their ancestors lived in Africa, Asia or Europe. For people all over the world who have been adopted, this kind of information can help them find out more about their roots. 23andMe provides data about the way people metabolize different drugs. It may be life-saving if you know how fast your body eliminates some anti-blood clotting drugs, or how well you may respond to some antibiotics or antidepressants. And then, there is information about carrier status for inherited disorders and disease risks. These data empower people to manage their own health better. And we always advise people to take the results to their doctor, especially if they indicate above average risk for serious diseases. Customers decide 23andMe lets the customer decide what he or she wants to know. If the customer does not want to know whether she has a BRCA1-mutation that increases her risks of getting breast cancer or ovarian cancer, it is easy to skip those parts. Francke: You really have to decide to open that file, and if you do not click on it, you won t be exposed to that part of the information. But what if people do open this file and find out they are at risk of getting a life-threatening disease? 23andMe has studied the impact of such bad news. Francke: This February, we published a study on the reactions of our customers to information about BRCA mutations. There were no extreme psychological reactions, most people who were told they had an increased cancer risk were glad they knew and started to inform their relatives. I m certain that many lives were saved this way in families with a high risk of breast cancer. We also studied how people dealt with negative results. People understood that a normal BRCA gene test did not mean that they were off the hook and that they may still have an elevated risk. Males with a BRCA gene mutation were aware of their own increased risk, but most of them were more concerned about the chance that they passed on this mutation to their daughters. All in all, I was impressed by the mature and rational reactions of people to this kind of information. Professor Uta Francke: DNA gives people, for instance people who have been adopted, information about their origins. (photos Thijs Rooimans)
5 8 Hub 10 HoBB special Hub 10 HoBB special 9 Keynote 2: Stephen Birch by Linda van den Berg Professor Stephen Birch addressed biobanks from a health economics perspective in his keynote lecture on 22 November. Holding appointments at universities in Canada, the UK and Australia, Stephen Birch is a truly international expert in health economics. For most people involved in biobanking, health economics is a whole new way of thinking about their field, says Birch. of biobanking initiatives is a challenge because their contribution to health is rather indirect. It is important that we ask ourselves: what will it achieve for the general population? Will it increase the wellbeing of the population? One of the promises of biobanks is that they will stimulate personalized medicine. From a health economist s perspective, personalized medicine offers an ideal solution to maximizing value for money. For instance, once it becomes possible to identify high-risk patients, it is also possible to single them out for certain expensive treatments. Professor Birch: Biobanks may improve the efficiency of healthcare by increasing the amount of information a medical doctor has about an individual patient. This improved efficiency would increase costeffectiveness of current healthcare systems. happens in health research: a health economist is brought in after clinical research has been finished. New technologies tend to race ahead and leave economics behind. So what is a health economist s view on biobanks? Economics is about choices: there are always limited resources available, so choices should be made. A new technological development adds to the available options.the economic analysis Idea Labs The HandsOn: Biobanks 2013 conference programme included three Idea Labs. These are interactive workshops aiming to provoke discussion about a certain theme. Professor Birch organized an Idea Lab about health economy aspects of biobanking at the 2012 edition of HandsOn: Biobanks. The format of an Idea Lab was a new experience to me; I had not seen that before. I was impressed by the level of engagement of the audience, they were very interested. This was also true of the audience at the 2013 edition, I could tell that there was a genuine interest and a realization that biobanks can play an important role in making care cost models operate more efficiently. Professor Stephen Birch: Economic aspects of biobanking are not properly understood. (photos Thijs Rooimans) Health economists are not only interested in the clinical effectiveness of healthcare, but also in its cost-effectiveness. Birch: Health economics is different from other branches of economy. In healthcare, there is a special relationship between supplier and consumer. The supplier usually decides what the consumer needs. This differs from the more traditional economic relationship between a car dealer and his customer. As health economists, we need to adjust our study methods to this special situation. The main challenge is to develop healthcare based on the needs of the population. Focusing on needs has led the field to shift from thinking in terms of health outcome to terms of wellbeing. The patient s health is a goal for healthcare professionals. From a patient s point of view, wellbeing is a more important goal. For instance, prenatal screening can provide a pregnant woman with knowledge. This knowledge will not necessarily improve her health, but it can improve her wellbeing because it enables her to plan ahead, explains Birch. Multimillion dollar operations The economic analysis of biobanking is a recent branch of health economics. Economic aspects of biobanking are not well understood. This is rather surprising given the fact that biobanking initiatives are often multimillion dollar operations. It is not a big topic in our field; there is a gap that needs filling. This often
6 10 Hub 10 HoBB special Hub 10 HoBB special 11 Keynote 3: Henk-Jan Guchelaar by Margot Heesakker Professor Henk-Jan Guchelaar (LUMC) delivered the third keynote speech on Biobanks and Drug Development on Friday 22 November. His speech, Personalized medicine where are we, really? was a foray into the past, present and future developments in individual health care, demonstrating that large steps are being taken already--but are they big enough? Can you say a bit more about where we are? Well, it is the oldest question in pharmacology: why does a given drug work really well for some patients, but not at all for others? Why does the same drug cause severe side-effects in some patients, while not in others? We know that, generally speaking, only 50% of all drugs are effective. For cancer, the success rate is even lower: only 25%. The first clue that there was a genetic component in the answer to this question stems from Motulsky s research, published in He demonstrated that the severe side-effects of primaquine as an anti-malaria drug in African- American soldiers in the Second World War were due to genetic differences. But it has taken quite some time until we were able, and it became affordable, to really research people s DNA in large numbers and find biomarkers. But there are other aspects, too. Just as a genetic predisposition for a certain disease does not automatically mean you will develop that disease, there are other factors at work: eating and drinking habits, general health, work, previous drug use. You have to draw up a model to predict the efficacy of treatment on almost an individual level. And, to successfully implement the knowledge we have on genetic biomarkers, you need to disseminate this knowledge in a way that makes it easy for the physician inevitable, in fact to see: this patient has a predisposition for side-effects using this drug. To facilitate this, we have drawn up guidelines, which are now implemented into the electronic prescription system used by GP s and pharmacists. It means that when they start to fill out a prescription, they will receive an automatic warning if there is a known contra-indication. So, basically, we are on the verge of taking some major steps, but we need more data. Much more data. And that is where biobanks come in? They might do, yes. As yet, there are few collaborations between the field of pharmacogenetics and biobanking. You see, for a biobank collection to be useful, we need not only DNA, but also a full drug history of five to eight hundred patients. Our sources are mainly clinical trials and archived materials, paraffin blocks from pathology departments. But that is exactly what BBMRI-NL has been doing the last four years or so: enabling existing biobanks to enrich their collections with for example data on drug use. Well, I know that the Leiden Longevity Study for example has GWAS data on a 1,000 participants. But even if the data are complete, that is to say including a full drug use history, there are ethical questions to be addressed: you cannot simply decide to use the data for a different purpose. Personalized medicine: from generic treatment to specifically targeted drugs. It s already happening, says Professor Guchelaar (photos Thijs Rooimans) There are ethical questions involved, like: would the participants have consented to further use if they knew that use could eventually lead to the development of drugs? What role can, or do, the pharmaceutical industry play in developing personalized medicine? Are they welcoming it? They are now. Five years ago, most pharmaceutical companies were still very reluctant to discuss the idea. Traditionally, the pharmaceutical industry has always tried to find so-called blockbuster drugs, drugs that will work for the majority of patients. But the rapid developments in genetic studies, and the discoveries of many, many biomarkers for diseases, means that they are having to change their ideas. In fact, all pharmaceutical companies now have a biomarker department. The focus is definitely switching to targeting sub-groups of diseases, developing far more specifically targeted drugs.
7 12 Hub 10 HoBB special HandsOn: Biobanks 2013: Communities Connected Sold Out, again! After hosting the first edition of HandsOn: Biobanks in Uppsala in 2012, I was a bit reluctant to hand over the baton. But in my opinion, BBMRI-NL and Professor Gert-Jan van Ommen have done an excellent job in keeping the format for HandsOn: Biobanks alive. Some impressions: On Thursday morning, the lecture room was filled up when Professor Uta Francke (Stanford School of Medicine) gave her keynote speech SNPs and surveys: Participant-driven research with selfreported data, about the advantages of research fuelled by paying consumers, as is the practice at 23andMe, the company of which Professor Francke is a board member. The speech got the audience thinking and talking. Just how topical the subject of industryconsumer driven biobanks is, was proven the following day, when 23andMe received an injunction from the U.S. Food and Drug Professor Jan-Eric Administration to stop selling their Litton (photo Thijs Rooimans) DNA tests, as the company hadn t complied with the FDA directive to discontinue new consumer access during their regulatory review process. At the heart of HandsOn: Biobanks was the interactive biobank exhibition The Route where you could follow the research process and discuss the value of biobank research for both society and current and future patients. Many brought their coffee to the Ethics café to listen to and discuss topics such as immortality and Sequencing the HeLa genome with Raeka Aiyar. HeLa is the most widely used model cell line for studying human cellular and molecular biology. After publishing the HeLa genome in the online journal G3: Genes, Genomes and Genetics, researchers at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, withdrew the data following a storm over the publication. During the two-day conference, visitors were able to attend three Idea Labs, which consisted of an introduction to a theme, followed by sub-sessions during which visitors followed up and discussed the subtheme of their choice with an expert and the other members of their group. I think that at least two of these Idea Lab groups are drawing up plans for future collaboration, a wonderful proof that the concept works and has real value. A personal highlight for me was the fact that on Friday 22 November, the news came through that BBMRI s ERIC-application had been officially approved by the EU commissioner. BBMRI-ERIC, with head offices in Graz, Austria, will start work on 1 February, 2014, with me at the helm as Director General. HandsOn: Biobanks gave a great opportunity to meet experts from all around the world in the biobanking area and to discuss future issues for biobanking. I want to thank all speakers and exhibitors for making this conference happen. I also want to give a great thanks to all visitors for showing that the biobanking area is important and interesting. Last but not least, I would like to thank everybody in the organizing committee who made this conference possible. And a special thanks goes to Mascha Jansen, the Project Manager for HandsOn: Biobanks This was the second version of HandsOn: Biobanks. The third version will take place September 2014 in Helsinki, Finland. BBMRI.fi and Professor Anu Jalanko will be your hosts. Looking forward to meeting you in Helsinki! Professor Jan-Eric Litton Director General BBMRI-ERIC About the author Jan-Eric Litton is Professor of Biomedical Computing Technology at the Karolinska Institutet, Stockholm, Sweden. He is Executive Director and head of BBMRI.se, and coordinates the Nordic BBMRI (Denmark, Sweden, Norway, Finland, Island, Faroe Island and Estonia). He also heads the development of e-epidemiology by using internet, cell-phones, digital paper and digital TV for collecting epidemiology data. Jan-Eric Litton is involved in 8 large EU projects in medicine, including the project BiobankCloud - Scalable, Secure Storage of Biobank Data. Colophon Hub 10, HandsOn: Biobanks 2013 special Hub is the official newsletter of BBMRI- NL (Biobanking and Biomolecular Research Infrastructure). It appears in a circulation of 1,000 copies and as a pdf on the BBMRI-NL website. To subscribe to Hub, info@bbmri.nl or register on en-gb/news/newsletter/ subscribe-to-printednewsletter. Subscriptions are free. Editorial board: Petra van Overveld Gert-Jan van Ommen Nicole van Scherrenburg Ronald Stolk Cisca Wijmenga Gerhard Zielhuis Editor-in-chief: Margot Heesakker-Heintz (m.heesakker@bbmri.nl) Contributions to this issue: Pieter van Megchelen Linda van den Berg Jan-Eric Litton Photography: Thijs Rooimans Lay-out: Margot Heesakker - Heintz Print: Printshop Ouwehand BBMRI-NL is part of BBMRI and is funded by the Netherlands Organisation for Scientific Research (NWO).
Information for patients and the public and patient information about DNA / Biobanking across Europe
Information for patients and the public and patient information about DNA / Biobanking across Europe BIOBANKING / DNA BANKING SUMMARY: A biobank is a store of human biological material, used for the purposes
More informationAttacking the Biobank Bottleneck
Attacking the Biobank Bottleneck Professor Jan-Eric Litton BBMRI-ERIC BBMRI-ERIC Big Data meets research biobanking Big data is high-volume, high-velocity and highvariety information assets that demand
More informationClinical Trials. Clinical trials the basics
Clinical Trials Clinical Trials This brochure is for people making decisions about cancer treatment. You may be thinking about a clinical trial for you or your child but need to know more before you decide.
More informationData in biobanking An emerging new era for data management
3. Main Topic DATA (Sessions C1-5) Data in biobanking An emerging new era for data management Medical University of Graz 21 / 43 C1 - Medical imaging and biobanking (radiology and digital pathology) Jan-Eric
More informationFINLAND ON A ROAD TOWARDS A MODERN LEGAL BIOBANKING INFRASTRUCTURE
Postrefereed, preprint version of the text published at European Journal of Health Law 2013(3)28994. Link to the publisher s website: http://www.brill.com/europeanjournalhealthlaw Sirpa Soini FINLAND ON
More informationBBMRI-NL awards thirty-four Complementation projects
Hub Hub is the official newsletter of BBMRI-NL The concept behind BBMRI-NL s Complementation projects remains the same: small-scale projects, improving the accessibility of existing biobanks for biomedical
More informationPhasel clinical trials:
Phasel clinical trials: what are they all about? Information for people wanting to know more about early clinical trials in cancer, Belfast City Hospital NORTHERN IRELAND CANCER TRIALS CENTRE Introduction
More informationTaking Part in Research at University Hospitals Birmingham
University Hospitals Birmingham NHS Foundation Trust The Trust provides free monthly health talks on a variety of medical conditions and treatments. For more information visit www.uhb.nhs.uk or call 0121
More informationBig Data in Biobanking towards targeted medicine
Big Data in Biobanking towards targeted medicine Ronald Stolk Professor Clinical Epidemiology, UMCG Board member Parelsnoer Institute Chief Scientific Officer LifeLines What is a biobank? Systematic collection
More informationPersonalised Healthcare Frequently Asked Questions
Personalised Healthcare Frequently Asked Questions Foreword In one sense, personalised healthcare is nothing new. It is what doctors have aimed to provide for their patients through the exercise of their
More informationData integration and modelling in health sciences Science as a conversation across borders
Open data key to the future Helsinki 2011-11-01 Data integration and modelling in health sciences Science as a conversation across borders Juni Palmgren Karolinska Institutet and FIMM, Helsinki University
More informationThe Importance of Sharing Medical Data
Diving into the Data Pool Exploring public views about the way medical data is shared Report from public event on 31 October 2013 Should it be easier for medical data to be shared to help research? What
More informationBreakthrough Lung Cancer Treatment Approved Webcast September 9, 2011 Renato Martins, M.D., M.P.H. Introduction
Breakthrough Lung Cancer Treatment Approved Webcast September 9, 2011 Renato Martins, M.D., M.P.H. Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer
More informationFINDINGS FROM AN INDEPENDENT EVALUATION OF THE AMNH s ONLINE SEMINARS ON SCIENCE COURSE: GENETICS, GENOMICS, GENETHICS
FINDINGS FROM AN INDEPENDENT EVALUATION OF THE AMNH s ONLINE SEMINARS ON SCIENCE COURSE: GENETICS, GENOMICS, GENETHICS Inverness Research studied the AMNH Seminars on Science program for eight years, from
More informationGenetic diagnostics the gateway to personalized medicine
Micronova 20.11.2012 Genetic diagnostics the gateway to personalized medicine Kristiina Assoc. professor, Director of Genetic Department HUSLAB, Helsinki University Central Hospital The Human Genome Packed
More informationprepared in making referrals through Choose and Book, which doesn t create any additional work for me.
Health Management Limited has been appointed as the supplier to deliver Fit for Work (previously Health and Work Service) in England and Wales. The following is a personal account of a service user s journey.
More informationHow Can Institutions Foster OMICS Research While Protecting Patients?
IOM Workshop on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials How Can Institutions Foster OMICS Research While Protecting Patients? E. Albert Reece, MD, PhD, MBA Vice
More informationHuman Research Protection Program University of California, San Diego ISSUES ON DNA AND INFORMED CONSENT
Human Research Protection Program University of California, San Diego ISSUES ON DNA AND INFORMED CONSENT Regulatory changes will occur for investigators studying human DNA The recent acceleration and widening
More informationMedicals c i e n t i f i c study
Medicals c i e n t i f i c study design risks medical-ethics review board 2 Table of contents M e d i c a l - s c i e n t i f i c study Preface 2 Introduction 4 Medical-scientific study 5 Why participate?
More informationGenetic Testing in Research & Healthcare
We Innovate Healthcare Genetic Testing in Research & Healthcare We Innovate Healthcare Genetic Testing in Research and Healthcare Human genetic testing is a growing science. It is used to study genes
More informationLifeLines Cohort Study. Salome Scholtens, Manager Research Office
LifeLines Cohort Study Salome Scholtens, Manager Research Office What is LifeLines? Biobank» LifeLines Cohort & Biorepository 165,000 participants at least 30 years follow-up Three generation design Northern
More informationDrs Beales, Crowley, Strachan & Navamani North Road Surgery, 77 North Road, Kew, Richmond, TW9 4HQ www.northroadsurgery.nhs.uk
24th March 2013 Drs Beales, Crowley, Strachan & Navamani North Road Surgery, 77 North Road, Kew, Richmond, TW9 4HQ www.northroadsurgery.nhs.uk Introduction North Road Surgery This report summarises the
More informationConsultation Response Medical profiling and online medicine: the ethics of 'personalised' healthcare in a consumer age Nuffield Council on Bioethics
Consultation Response Medical profiling and online medicine: the ethics of 'personalised' healthcare in a consumer age Nuffield Council on Bioethics Response by the Genetic Interest Group Question 1: Health
More informationIn recent years the number of DNA genetic tests that you can
Inside How accurate are the tests? 2 How useful are the tests? 2 What can Direct-to-Consumer DNA genetic tests tell me? 2 What happens to my personal information? 3 What protections are there in Australia?
More informationINFORMATION FOR PATIENTS AND THEIR FAMILIES. You can live a healthy life, if you get treatment early
INFORMATION FOR PATIENTS AND THEIR FAMILIES Hemochromatosis AN IRON OVERLOAD DISEASE You can live a healthy life, if you get treatment early Department of Health and Human Services Centers for Disease
More informationA responsible approach to clinical trials. Bioethics in action
A responsible approach to clinical trials Bioethics in action What is bioethics? At Novo Nordisk bioethics is the expression used for all ethical issues related to the use of life science technologies
More informationRevision of the Directive 98/79/EC on In Vitro Diagnostic Medical Devices. Response from Cancer Research UK to the Commission August 2010
Revision of the Directive 98/79/EC on In Vitro Diagnostic Medical Devices Response from Cancer Research UK to the Commission August 2010 1. Cancer Research UK (CR-UK) 1 is leading the world in finding
More informationThe University of Texas Southwestern Medical Center at Dallas Retina Foundation of the Southwest CONSENT TO PARTICIPATE IN RESEARCH
The University of Texas Southwestern Medical Center at Dallas Retina Foundation of the Southwest CONSENT TO PARTICIPATE IN RESEARCH Title of Research: Funding Agency/Sponsor: Study Doctors: Research Personnel:
More informationGuidelines for health professionals about DNA / Biobanking in Europe
Guidelines for health professionals about DNA / Biobanking in Europe BIOBANKING SUMMARY A "biobank" is a: "service unit, non-profit organization for the collection and preservation of biological material
More informationPharmaceutical Business Plan Dawn Romvari-Mihalyi Cellular 917-208-7366
Pharmaceutical Business Plan Dawn Romvari-Mihalyi Cellular 917-208-7366 1.0 Executive Summary 2.0 Situation Analysis 2.1 Market Summary 2.1.1 Market Demographics 2.1.2 Market Needs 2.1.3 Market Trends
More informationClinical Research from EHR data
Clinical Research from EHR data Gunnar O Klein professor in Health Informatics at NSEP Norwegian Centre for EHR Research Workshop at HelseIT in Trondheim 2012-09-19 1 Purpose of the workshop Together with
More informationPublic Health and. Interdisciplinary Context. Birgitta Edlund RNT
1 Public Health and Caring Science Nursing Education in an Extended Interdisciplinary Context Birgitta Edlund RNT Associate Professor 2 Uppsala 3 University Main Building 4 Uppsala University Research
More informationThe Pre-Medical Program. Start your career in medicine at University College Roosevelt. www.ucr.nl
The Pre-Medical Program Start your career in medicine at University College Roosevelt www.ucr.nl University College Roosevelt Pre-Medical Program University College Roosevelt (UCR) is the international
More informationInformation Technology in Healthcare
Project name Seminar Report Information Technology in Healthcare Authors Thirza van den Broek Venla Virkamäki On Tuesday May 19, 2015, the Embassy of the Kingdom of the Netherlands together with Philips
More informationBRCA Genes and Inherited Breast and Ovarian Cancer. Patient information leaflet
BRCA Genes and Inherited Breast and Ovarian Cancer Patient information leaflet This booklet has been written for people who have a personal or family history of breast and/or ovarian cancer that could
More informationRESEARCH INVOLVING HUMAN SUBJECTS
RESEARCH INVOLVING HUMAN SUBJECTS GUIDELINES FOR IRBS PART A: INTRODUCTION AND CURRENT FRAMEWORK SECTION I: INTRODUCTION 1. Introduction About these Guidelines 1.1. The Bioethics Advisory Committee (BAC)
More informationPatient Centricity and the Changing Landscape of Healthcare
Patient Centricity and the Changing Landscape of Healthcare Andrea Cotter Director Healthcare Marketing IBM Corporation IBM Healthcare and Life Sciences Patient Centricity and the Changing Landscape of
More informationWhat Lawyers Don t Tell You The Realities of Record Keeping
What Lawyers Don t Tell You The Realities of Record Keeping Welcome to the Power of Attorney Podcast which is part of our Conversations that Matter Podcasts. My name is Mary Bart, Chair of Caregiving Matters.
More informationSAVING LIVES: ACHIEVING MORE
SAVING LIVES: ACHIEVING MORE Anthony Nolan Organisational strategy for 2015-2018 Where we re coming from In 1974, we were the world s first stem cell donor register. And over 40 years later, we re at the
More informationP a g e 1 REMARKS BY THE HONOURABLE PETER UNDERWOOD AC, GOVERNOR OF TASMANIA AT THE OPENING OF THE 10 TH ANNUAL SCIENTIFIC MEETING OF MEDICAL IMAGING AND RADIATION THERAPY, HOBART FRIDAY 8 TH MARCH 2013
More informationContinuing education for community pharmacists in Denmark the case of Master of Drug Management
Continuing education for community pharmacists in Denmark the case of Master of Drug Management Birthe Søndergaard Associate Professor Department of Pharmacology and Pharmacotherapy, Section of Social
More informationIt s our people that make the difference
It s our people that make the difference 2 CONTENTS Welcome page 2 About KeyGene page 3 Personal & Professional page 4 KeyGene offers page 11 KeyGene Learning Academy page 13 Keep in Touch page 14 3 WELCOME
More informationUNIVERSITY MEDICAL CENTRE PATIENT PARTICIPATION GROUP ANNUAL REPORT & ACTION PLAN 2012-13
UNIVERSITY MEDICAL CENTRE PATIENT PARTICIPATION GROUP ANNUAL REPORT & ACTION PLAN 2012-13 Introduction & Recruitment of the Patient Participation Group Review on how and why the Patient group was established:
More informationHealthcare Coalition on Data Protection
Healthcare Coalition on Data Protection Recommendations and joint statement supporting citizens interests in the benefits of data driven healthcare in a secure environment Representing leading actors in
More informationPfizer Oncology. Guest Expert: Louis Denis, MD Director of Clinical Research, Pfizer Oncology. www.wnpr.org. www.yalecancercenter.
Pfizer Oncology Guest Expert: Louis, MD Director of Clinical Research, Pfizer Oncology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Drs. Ed and Ken Miller. I am Bruce
More informationBiobanks: DNA and Research
f r o m b i r t h to death a n d b e n c h to clinic THE HASTINGS CENTER Bioethics Briefing Book for Journalists, Policymakers, and Campaigns Chapter 3 Biobanks: DNA and Research Karen J. Maschke, Biobanks:
More informationResumen Curricular de los Profesores. Jesse Boehm
Resumen Curricular de los Profesores Jesse Boehm Jesse Boehm is the assistant director of the Cancer Program at the Broad Institute. In this role, he works closely with Cancer Program director Todd Golub
More informationHow To Change Medicine
P4 Medicine: Personalized, Predictive, Preventive, Participatory A Change of View that Changes Everything Leroy E. Hood Institute for Systems Biology David J. Galas Battelle Memorial Institute Version
More informationThe NeurOmics team at a recent project meeting
Introduction Welcome to the NeurOmics project newsletter. This is the second edition and comes after the project has been underway for just over a year. This means that whilst we still have lots of work
More informationPatient Handbook on Stem Cell Therapies
Patient Handbook on Stem Cell Therapies Appendix I of the Guidelines for the Clinical Translation of Stem Cells www.isscr.org 2008, International Society for Stem Cell Research 2 Introduction We have all
More informationWhat s In Your Genes: How changes in the BRCA1/BRCA2 genes
ESSENTIALS BRCA1/BRCA2 Mutations What s In Your Genes: How changes in the BRCA1/BRCA2 genes might affect you and your family Our genes contain the codes for producing the proteins that are the building
More informationA guide to prostate cancer clinical trials
1 A guide to prostate cancer clinical trials In this fact sheet: What is a clinical trial? Why are trials done? What are trials looking into at the moment? How are clinical trials done? Should I take part
More informationHow to Pass Physics 212
How to Pass Physics 212 Physics is hard. It requires the development of good problem solving skills. It requires the use of math, which is also often difficult. Its major tenets are sometimes at odds with
More informationBIOSCIENCES COURSE TITLE AWARD
COURSE TITLE AWARD BIOSCIENCES As a Biosciences undergraduate student at the University of Westminster, you will benefit from some of the best teaching and facilities available. Our courses combine lecture,
More informationU.K. Familial Ovarian Cancer Screening Study (UK FOCSS) Phase 2 Patient Information Sheet
U.K. Familial Ovarian Cancer Screening Study (UK FOCSS) Phase 2 Patient Information Sheet 1. Invitation You are being invited to take part in a research study. Before you decide it is important for you
More informationEU Regulation on in-vitro Diagnostic Medical Devices call for urgent action.
EU Regulation on in-vitro Diagnostic Medical Devices call for urgent action. The European Commission issued a proposal for a new Regulation on in vitro diagnostic devices in September 2012. At the committee
More informationHealth Program in the Library of Alexandria
Submitted on: 4 August 2015 Health Program in the Library of Alexandria Suzanne Samir Head of Educational Services Section, Library of Alexandria, Alexandria, Egypt. suzanne.samir@bibalex.org Copyright
More informationBI & IM SYMPOSIUM CALL FOR SPONSORS
BI & IM SYMPOSIUM CALL FOR SPONSORS 24 TH AND 25 TH OF NOVEMBER 2014 By participating as a sponsor to the Business Intelligence & Information Management Symposium 2014 you have access to high level contacts
More informationClinical trials: The EU perspective. Dr Karim Berkouk, Deputy Head of Unit DG for Research and Innovation Health Directorate European Commission
Clinical trials: The EU perspective Dr Karim Berkouk, Deputy Head of Unit DG for Research and Innovation Health Directorate European Commission Content 1.EU: The global picture 2.EU & Clinial trials: The
More informationBRING YOUR RESEARCH TO LIFE
NIHES AT A GLANCE RESEARCH TRAINING IN MEDICINE AND THE HEALTH SCIENCES BRING YOUR RESEARCH TO LIFE 71% of all NIHES papers are published in the top 10% of the highest-impact journals. Source: Journal
More informationImmune Cell Studies in Type 1 Diabetes (ISTID) INFORMATION SHEET FOR ADULTS WITH NEWLY- DIAGNOSED DIABETES. Sponsored by Cardiff University
Immune Cell Studies in Type 1 Diabetes (ISTID) INFORMATION SHEET FOR ADULTS WITH NEWLY- DIAGNOSED DIABETES Sponsored by Cardiff University Chief Investigator Wales: Professor Colin Dayan Address: Centre
More informationSuperbike Surgery Ltd
Filecamp Case Study Superbike Surgery Ltd Jim Wright-Roberts Superbike Surgery Ltd superbikesurgery.co.uk There was a time when marketing firms, advertising agencies, in-house studios, photographers, and
More informationPersonalized medicine in China s healthcare system
Personalized medicine in China s healthcare system Jingmin Kan, Sam Linsen Netherlands office for Science and Technology, Guangzhou and Shanghai, China Content PERSONALIZED MEDICINE 2 FOCUS AT THE INDIVIDUAL
More informationWhy Disruptive Innovations Matter in Laboratory Diagnostics
Article: S. Nam.. Clin Chem 2015;61:935-937. http://www.clinchem.org/content/61/7/935.extract Guest: Spencer Nam is a Research Fellow specializing in healthcare at the Clayton Christensen Institute for
More informationITT Advanced Medical Technologies - A Programmer's Overview
ITT Advanced Medical Technologies (Ileri Tip Teknolojileri) ITT Advanced Medical Technologies (Ileri Tip Teknolojileri) is a biotechnology company (SME) established in Turkey. Its activity area is research,
More informationGuidance on Withdrawal of Subjects from Research: Data Retention and Other Related Issues
Office for Human Research Protections (OHRP) Department of Health and Human Services (HHS) Guidance on Withdrawal of Subjects from Research: Data Retention and Other Related Issues This guidance represents
More informationParticipating in Alzheimer s Disease Clinical Trials and Studies
Participating in Alzheimer s Disease Clinical Trials and Studies FACT SHEET When Margaret was diagnosed with earlystage Alzheimer s disease at age 68, she wanted to do everything possible to combat the
More informationGenes for Good Consent Form
Genes for Good Consent Form Version 2.1 The next few screens contain information about Genes for Good and the benefits and risks of participating. This is called "informed consent", because we want you
More informationFor 130 years, quality has been our standard.
For 130 years, quality has been our standard. Petrik Lajos Bilingual Vocational School of Chemistry, Environmental Protection and Information Technology, Budapest, Hungary Comenius Multilateral Partnership
More informationAm I at Risk for type 2 Diabetes? Taking Steps to Lower the Risk of Getting Diabetes NATIONAL DIABETES INFORMATION CLEARINGHOUSE
NATIONAL DIABETES INFORMATION CLEARINGHOUSE Am I at Risk for type 2 Diabetes? Taking Steps to Lower the Risk of Getting Diabetes U.S. Department of Health and Human Services National Institutes of Health
More informationPosition Statement on Doctors' Relationships with Industry 2010
Position Statement on Doctors' Relationships with Industry 2010 This document provides guidance for doctors on maintaining ethical relationships with the pharmaceutical industry, medical device and technology
More informationA Guide to Clinical Trials
A Guide to Clinical Trials For young people with cancer and their parents Children s Cancer and Leukaemia Group www.cclg.org.uk Original booklet produced in conjunction with the CCLG Patient Advocacy Committee.
More informationEPF Position Statement on the European Commission s proposal for a Regulation on In Vitro Medical Devices
EPF Position Statement on the European Commission s proposal for a Regulation on In Vitro Medical 03/09/2013 In Vitro Diagnostic medical devices include all tests performed to provide a diagnosis by assessing
More informationMolecular Biotechnology Master s Degree Program
> APPLIED LIFE SCIENCES Master s Degree Program: > FULL TIME Molecular Biotechnology Master s Degree Program www.fh-campuswien.ac.at My Occupational Future. Your Career Opportunities Biotechnology is one
More informationThe Hottest Recruiting Scripts in MLM by Eric Worre
The Hottest Recruiting Scripts in MLM by Eric Worre It s a stone cold fact that we have a better way, now let s go tell the world For more information on how to become a Network Marketing Professional,
More informationCLINICAL TRIALS WITH MEDICINES IN EUROPE
CLINICAL TRIALS WITH MEDICINES IN EUROPE REGULATORY FRAMEWORK FOR CLINICAL TRIALS WITH MEDICINES IN EUROPE The pharmaceutical industry is the most highly regulated sector in Europe. The Commission has
More informationGenome Sequencing. No: insurance companies and employers should not have access to this information:
Genome Sequencing 1. Health Care and the Human Genome: There is an interesting worry in the vicinity of the genetic engineering debate: How will the ever-lowering costs of sequencing DNA affect the health
More informationVariety in the HD gene s on switch affects when symptoms arise. By Melissa Christianson on May 29, 2015 Edited by Dr Jeff Carroll
Huntington s disease research news. In plain language. Written by scientists. For the global HD community. Switching it up: variety in the HD gene affects symptom onset Variety in the HD gene s on switch
More informationWhat Cancer Patients Need To Know
Taking Part in Clinical Trials What Cancer Patients Need To Know NATIONAL INSTITUTES OF HEALTH National Cancer Institute Generous support for this publication was provided by Novartis Oncology. Taking
More informationEMBL. International PhD Training. Mikko Taipale, PhD Whitehead Institute/MIT Cambridge, MA USA
EMBL International PhD Training Mikko Taipale, PhD Whitehead Institute/MIT Cambridge, MA USA Why create an EMBL? The structure of DNA had been solved and first protein structures were being identified
More informationOPEN INNOVATION STRATEGIES IN THE HEALTHCARE INDUSTRY
NINESIGMA WHITE PAPER OPEN INNOVATION STRATEGIES IN THE HEALTHCARE INDUSTRY How six leading healthcare companies are leveraging Open Innovation to achieve their innovation goals By: Stephen Clulow, Director
More informationThe Ethics of Research with Stored Samples and Data
The Ethics of Research with Stored Samples and Data Sara Chandros Hull, Ph.D. Office of the Clinical Director, NHGRI and Department of Bioethics National Institutes of Health Disclaimers/Disclosures No
More informationImpact of Breast Cancer Genetic Testing on Insurance Issues
Impact of Breast Cancer Genetic Testing on Insurance Issues Prepared by the Health Research Unit September 1999 Introduction The discoveries of BRCA1 and BRCA2, two cancer-susceptibility genes, raise serious
More informationPlease Step Out of The Car
Urban Survival Guide: Please Step Out of The Car A Step by Step Guide Through The Los Angeles DUI & DMV Process MR DUI LA Attorney Mark Rosenfeld The Law Office of Mark Rosenfeld 800-9700-DUI (384) MRDUILA.com
More informationINFORMATION LEAFLET. If anything is not clear, or if you would like more information, please
BIO INFOBK 1492 0410:Layout 1 21/04/2010 15:24 Page 1 INFORMATION LEAFLET You are being invited to take part in a major medical research project called UK Biobank. The purpose of UK Biobank is to set up
More informationThe Ear Foundation is an NGO: Impact of deafness for adults is under recognised: Each year we... And at work...
Adult implantation : quality of life? Sue Archbold, PhD Euro CI Users Antwerp, April 215 The Ear Foundation is an NGO: Family programme Education programme Sound Advice Research Each year we... reach 1,5
More informationPPG / vppg Patient Survey Report Updated 22 nd March 2012
Dr A Augustine Jenner Health Centre Dr M V Edwards 201 Stanstead Road Dr C Lamptey Forest Hill Dr R M Rowland SE23 1HU Dr A Sykes Tel: 020 3049 2960 Dr S Van Cooten Fax: 020 3049 2961 Dr A Warsop Practice
More informationImportant information about authorizations and appeals
Annual NEWSletter Important information about authorizations and appeals 2013 A publication of for CHIP and STAR members and their parents. Sometimes the care you get from your doctor needs prior approval.
More informationTargeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia EXECUTIVE SUMMARY. New England Healthcare Institute
Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia New England Healthcare Institute NEHI Innovation Series March 2004 Executive Summary From drugs and medical devices, to information
More informationUK hiking tourism. CH - Visitnorway.com
UK hiking tourism CH - Visitnorway.com Contents 1. Executive Summary 3 2. Introduction 4 3. Research on the Internet: Phase 1 5 3.01: Tour operators: 5 3.02: Websites/forums: 5 3.03: Hiking/Outdoor magazines
More informationVISUAL COMMUNICATION NEWS
SCHOOL OF ART & DESIGN VISUAL COMMUNICATION NEWS BA (HONS) ANIMATION BA (HONS) ART & DESIGN MEDIA PRACTICE (ONE YEAR TOP-UP) BA (HONS) GRAPHIC DESIGN BA (HONS) PHOTOGRAPHY FdA MEDIA CREATIVES IMAGES: FINAL-YEAR
More information2. ABOUT THE HUMAN GENETICS COMMISSION (HGC) 4. WHAT ARE THE CURRENT LAWS/LEGISLATION AROUND GENETIC TESTING?
Genes direct: Ensuring the effective oversight of genetic tests supplied directly to the public (A report by the Human Genetics Commission, March 2003) SUMMARY: Below is a five-page summary of the UK Human
More informationSYLLABUS PSYCHOLOGY 4SC6: SCIENCE COMMUNICATION Department of Psychology, Neuroscience, and Behaviour McMaster University 2014-2015
1 SYLLABUS PSYCHOLOGY 4SC6: SCIENCE COMMUNICATION Department of Psychology, Neuroscience, and Behaviour McMaster University 2014-2015 Course Meeting Information: Wednesdays 4:30-6:30pm in PC316 (class);
More informationBIG DATA. Workshop. 16 th European Health Forum Gastein REPORT - OCTOBER 2013
BIG DATA Workshop 16 th European Health Forum Gastein REPORT - OCTOBER 2013 The Big Data Workshop was organised by the European Alliance for Personalised Medicine and supported by the Lithuanian Health
More informationClinical Trials at PMH
Clinical Trials at PMH What You Need To Know UHN Patient Education Improving Health Through Education A Guide for Patients, Their Families and Friends in the PMH Cancer Program This information is to be
More informationschool resource CREATE DEBATE THE
school resource CREATE THE DEBATE welcome The Create the Debate pack has been produced by Parliament s Education Service with help from the UK Youth Parliament and BBC Three s Free Speech. This easy-to-use,
More informationWhere World-Class Expertise and Genuine Compassion Come Together. AT THE FOREFRONT OF TRANSPLANT CARE Kidney Combined Kidney-Pancreas Pancreas Islets
Where World-Class Expertise and Genuine Compassion Come Together 0011000110100111100110111100000101010011000101100010111000010010000100010000100001011110101010101111000 000010111000101110011000110100111100110111100000101010011000101100010111000010010000100010000100
More informationThe agency perspective: What we do and how we do it
The agency perspective: What we do and how we do it Tim Ryder and Olga Dai 15 July 2011 Who are we? Tim Ryder Scientific Team Leader, Darwin HC MA in Biochemistry; DPhil in Physiology 10 years of experience
More informationThis presentation has been put together by DDRC Healthcare. It focuses on a basic understanding of alcohol, and some of DDRC s research findings from
This presentation has been put together by DDRC Healthcare. It focuses on a basic understanding of alcohol, and some of DDRC s research findings from a study, recently conducted by them, which looked at
More informationTEAM CAPTAIN INFORMATION
TEAM CAPTAIN INFORMATION TEAM CAPTAIN INFO PACKET Everything you need to lead your Team to a fundraising victory! Date & Time: Saturday, September 12, 2015 3pm Registration & Party Begins 5pm Walk/Run
More information